Negative Symptoms in Schizophrenia: Correlation with Clinical and Genetic Factors

Hajj, Aline; Hallit, Souheil; Chamoun, Karam; Sacre, Hala; Obeïd, Sahar; Haddad, Chadia; Dollfus, Sonia; Khabbaz, Lydia Rabbaa

doi:10.2217/pgs-2020-0171

Cited by 4 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the DDD for typical and atypical anti-psychotics had not shown any statistically significant correlation with either SNS total or subdomain scores. These findings are somehow inconsistent with results obtained in a previous Lebanese study, 32 where the total SNS score was significantly correlated with the total daily dose of chlorpromazine-equivalent and a higher daily dose of chlorpromazine-equivalent for typical anti-psychotics, while it was negatively related to a higher chlorpromazine-equivalent daily dose for atypical anti-psychotics. This contradiction could perhaps be explained by the difference in the mean of the total equivalent dose of chlorpromazine among patients in Hajj, et al 30 (1150.91 ± 973.70 mg), which is mainly composed of typical anti-psychotics (1010.57 ± 973.63 mg), more than the newer atypical group (163.57 ± 305.97 mg).…”

Section: Discussioncontrasting

confidence: 99%

“…Consistent with our findings, no serious correlation was found between either gender or age with medication adherence in Alsalem's study. 25 Nevertheless, there are inconsistencies between the current study findings and those of Hajj et al 32 with regard to the analyses of negative symptoms, as older age patients and female gender were considerably connected with higher scores of SNS (p<0.001).…”

Section: Discussioncontrasting

confidence: 99%

“…Li et al 33 showed a similar outcome, which was attributed to the probability of better psychological adjustment and improved patient physical health in married patients. On the contrary, Hajj et al 32 showed that married patients were more likely to have negative symptoms than single or divorced patients (p<0.017).…”

Section: Discussionmentioning

confidence: 94%

See 2 more Smart Citations

Correlation Between Efficacy of Treatment with Anti-psychotics and Adherence in Schizophrenic Patients: A Cross-sectional Study in Saudi Arabia

Shilbayeh,

Al-Dosari,

Al-Sahabi

et al. 2023

Ind. J. Pharm. Edu. Res.

View full text Add to dashboard Cite

Background: Schizophrenic patients' adherence to medication regimens can determine clinical outcome success. This study focuses on medication adherence and its correlation with the efficacy of anti-psychotics. The study's goal is to (1) assess the efficacy of anti-psychotics and adherence using the Self-evaluation of Negative Symptoms (SNS) tool and Medication Adherence Rating Scale (MARS), and (2) examine the demographic and clinical factors that could impact both outcomes (SNS and MARS). Materials and Methods: Between November 2021 and February 2022, a cross-sectional study was carried out. Only 45 of 100 schizophrenia patients screened were included in the sample. MARS and SNS self-assessment questionnaires that took approximately 15 min to complete were administered to patients in a scheduled clinic interview. Other patients' demographic, physical, and clinical information was gathered from their electronic medical records via a Redcap designed data collection sheet. Results: Almost 53.3% of the current schizophrenic patients had perceived mild negative symptoms (scored 1 to <20 out of 40 on SNS). Surprisingly, 64.4% were either poor adherent (n=13 scored 5 to 6) or non-adherent (n=16 scored <5). There was a notable negative correlation between the total MARS score and both total SNS (r = -0.325, p=0.03) and social withdrawal scores (r = -0.436, p=0.003). Non-adherence was significantly associated with lower education levels (p=0.028) and unemployment (p=0.008), whereas SNS total score and anhedonia were both markedly associated with different marital status (p=0.046, and p=0.016, respectively). Conclusion: According to the study, medication schizophrenia nonadherence correlates negatively with the efficacy of anti-psychotics as perceived by patients, which reflects patient quality and perception of life. These findings strongly emphasize the importance of developing adherence interventions to enhance compliance with anti-psychotic regimens and improve patients' perceived self-evaluation of negative symptoms.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Correlation Between Efficacy of Treatment with Anti-psychotics and Adherence in Schizophrenic Patients: A Cross-sectional Study in Saudi Arabia

Shilbayeh,

Al-Dosari,

Al-Sahabi

et al. 2023

Ind. J. Pharm. Edu. Res.

View full text Add to dashboard Cite

show abstract

“…In our study, patients with predominantly negative symptoms exhibited cognitive impairment, particularly in the domains of processing speed and attention, which may be related to the neural mechanisms associated with these symptoms. The negative symptoms of psychosis are thought to arise from disruptions in genetic variants of the dopamine pathway 22 and hypodopaminergic activity in the mesocortical pathway and prefrontal cortex, 23 which are responsible for cognitive and emotional processing. The dysfunction of these pathways may lead to slower information processing and lower attention, resulting in deficits in cognitive performance.…”

Section: Discussionmentioning

confidence: 99%

Cognitive Impairments in Drug-Naive Patients With First-Episode Negative Symptom–Dominant Psychosis

Zhang,

Wei,

Tang

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceAvailable antipsychotic medications are predominantly used to treat positive symptoms, such as hallucinations and delusions, in patients with first-episode psychosis (FEP). However, treating negative and cognitive symptoms, which are closely related to functional outcomes, remains a challenge.ObjectiveTo explore the cognitive characteristics of patients with negative symptom–dominant (NSD) psychosis.Design, Setting, and ParticipantsThis large-scale cross-sectional study of patients with FEP was led by the Shanghai Mental Health Center in China from 2016 to 2021, with participants recruited from 10 psychiatric tertiary hospitals. A comprehensive cognitive assessment was performed among 788 patients with FEP who were drug-naive. Symptom profiles were determined using the Positive and Negative Symptoms Scale (PANSS), and NSD was defined as a PANSS score for negative symptoms higher than that for positive and general symptoms. Positive symptom–dominant (PSD) and general symptom–dominant (GSD) psychosis were defined similarly. Data were analyzed in 2023.ExposurePsychotic symptoms were categorized into 3 groups: NSD, PSD, and GSD.Main Outcomes and MeasuresNeurocognitive performance, assessed using the Chinese version of the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery.ResultsThis study included 788 individuals with FEP (median age, 22 [IQR, 17-28] years; 399 men [50.6%]). Patients with NSD exhibited more-pronounced cognitive impairment than did those with PSD or GSD. Specifically, cognitive differences between the NSD and PSD group, as well as between the NSD and GSD group, were most notable in the processing speed and attention domains (Trail Making [F = 4.410; P = .01], Symbol Coding [F = 4.957; P = .007], Verbal Learning [F = 3.198; P = .04], and Continuous Performance [F = 3.057; P = .05]). Patients with PSD and GSD showed no significant cognitive differences. Cognitive impairment was positively associated with the severity of negative symptoms. Most of the cognitive function tests used were able to differentiate patients with NSD from those with PSD and GSD, with significant differences observed across a range of tests, from Brief Visuospatial Memory Test–Revised (χ2 = 3.968; P = .05) to Brief Assessment of Cognition in Schizophrenia symbol coding (χ2 = 9.765; P = .002).Conclusions and RelevanceThe findings of this cross-sectional study of patients with FEP suggest the presence of a clinical subtype characterized by a predominance of negative symptoms and cognitive impairment.

show abstract

“…A recent pharmacogenomic study on treatment response to risperidone used an SNP microarray-based GWAS and whole-exome sequencing-based GWAS to identify genetic variants underlying antipsychotic responses which may ultimately facilitate precision medicine in schizophrenia (Zhao et al , 2022). Furthermore, research on the genetic underpinnings of positive and negative symptom score domains and cognitive deficit in schizophrenia has discovered shared and distinct gene associations for the symptom domains and cognitive deficit (Xavier and Vorderstrasse, 2017; Hajj et al , 2021; Wu et al , 2021). In addition, polygenetic risk scores were employed to evaluate the relationship between schizophrenia genetic liability and phenotypic features (Mallet et al , 2020; Richards et al , 2020; Legge et al , 2021).…”

Section: Discussionmentioning

confidence: 99%

Gene and schizophrenia in the pregenome and postgenome-wide association studies era: a bibliometric analysis and network visualization

Zakaria¹,

Sasongko²,

Al-Rahbi³

et al. 2023

Psychiatric Genetics

View full text Add to dashboard Cite

This study aimed to perform a bibliometric analysis on genetic studies in schizophrenia in the pregenome-wide association studies (GWAS) and post-GWAS era. We searched the literature on genes and schizophrenia using the Scopus database. The documents increased with time, especially after the human genome project and International HapMap Project, with the highest citation in 2008. The top occurrence author keywords were discovered to be different in the pre-GWAS and post-GWAS eras, reflecting the progress of genetic studies connected to schizophrenia. Emerging keywords highlighted a trend towards an application of precision medicine, showing an interplay of environmental exposures as well as genetic factors in schizophrenia pathogenesis, progression, and response to therapy. In conclusion, the gene and schizophrenia literature has grown rapidly after the human genome project, and the temporal variation in the author keywords pattern reflects the trend of genetic studies related to schizophrenia in the pre-GWAS and post-GWAS era.

show abstract

Negative Symptoms in Schizophrenia: Correlation with Clinical and Genetic Factors

Cited by 4 publications

References 62 publications

Correlation Between Efficacy of Treatment with Anti-psychotics and Adherence in Schizophrenic Patients: A Cross-sectional Study in Saudi Arabia

Correlation Between Efficacy of Treatment with Anti-psychotics and Adherence in Schizophrenic Patients: A Cross-sectional Study in Saudi Arabia

Cognitive Impairments in Drug-Naive Patients With First-Episode Negative Symptom–Dominant Psychosis

Gene and schizophrenia in the pregenome and postgenome-wide association studies era: a bibliometric analysis and network visualization

Contact Info

Product

Resources

About